Search

everythinglearnresearchcommunity

for

Search:↓

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

New mutations in the hairless gene may cause hair loss and affect bone development.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Mice with human-like EGFR had growth issues, skin defects, heart problems, and unusual bone development.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

The mTOR pathway may be involved in the development of hair follicle tumors, with higher activity in malignant tumors.

Melanocyte pathology requires keratinocyte hyperplasia and regulation dysfunction.

Matriptase-2 helps control iron levels by suppressing hepcidin, and its deficiency can cause iron-deficiency anemia.

A specific protein complex increases the activity of a plant enzyme, but this action is not required for plant root hair growth.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

The MBTPS2 gene variant c.970+5G>A is a common mutation causing IFAP syndrome.

New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.

Applying a specific inhibitor lightens skin and hair color.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Dermal EZH2 controls skin cell growth and differentiation in mice.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

The report expanded knowledge of MBTPS1-related disorders by identifying new symptoms.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

The rash resolved after stopping ponatinib.

A specific gene mutation (Y449H in K10) was found in a patient with severe skin disorder.

The research suggests that Tourette syndrome is linked to both brain signaling and immune system pathways.

The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

The Kras mutation changes normal cell signals, leading to disrupted tissue structure and potential cancer.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

A new gene mutation linked to KID syndrome was found, expanding genetic knowledge.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.